David J Timson

List of Publications by Year
in descending order

182	4,940	94433 37	128289 60
papers	citations	h-index	g-index

186	186	186	5140
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Is there a common water-activity limit for the three domains of life?. ISME Journal, 2015, 9, 1333-1351.	9.8	229
2	The biology of habitat dominance; can microbes behave as weeds?. Microbial Biotechnology, 2013, 6, 453-492.	4.2	205
3	A universal measure of chaotropicity and kosmotropicity. Environmental Microbiology, 2013, 15, 287-296.	3.8	172
4	Chaotropicity: a key factor in product tolerance of biofuel-producing microorganisms. Current Opinion in Biotechnology, 2015, 33, 228-259.	6.6	160
5	The 67 kDa laminin receptor: structure, function and role in disease. Bioscience Reports, 2008, 28, 33-48.	2.4	155
6	DNA ligases in the repair and replication of DNA. Mutation Research DNA Repair, 2000, 460, 301-318.	3.7	150
7	Multiplication of microbes below 0.690 water activity: implications for terrestrial and extraterrestrial life. Environmental Microbiology, 2015, 17, 257-277.	3.8	131
8	Hydrophobic substances induce water stress in microbial cells. Microbial Biotechnology, 2010, 3, 701-716.	4.2	118
9	Molecular Structure of Human Galactokinase. Journal of Biological Chemistry, 2005, 280, 9662-9670.	3.4	94
10	Galactokinase: structure, function and role in type II galactosemia. Cellular and Molecular Life Sciences, 2004, 61, 2471-2484.	5.4	88
11	The biochemical basis of hereditary fructose intolerance. Journal of Inherited Metabolic Disease, 2010, 33, 105-112.	3.6	87
12	Structure of the adenylation domain of an NAD+-dependent DNA ligase. Structure, 1999, 7, 35-42.	3.3	84
13	Functional domains of an NAD + -dependent DNA ligase 1 1Edited by A. R. Fersht. Journal of Molecular Biology, 1999, 285, 73-83.	4.2	77
14	The N-terminus of A1-type myosin essential light chains binds actin and modulates myosin motor function. FEBS Journal, 1998, 255, 654-662.	0.2	69
15	Functional analysis of disease-causing mutations in human galactokinase. FEBS Journal, 2003, 270, 1767-1774.	0.2	69
16	NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 663-676.	2.3	68
17	Coumarin-Based Inhibitors of Human NAD(P)H:Quinone Oxidoreductase-1. Identification, Structureâ€“Activity, Off-Target Effects and In Vitro Human Pancreatic Cancer Toxicity. Journal of Medicinal Chemistry, 2007, 50, 6316-6325.	6.4	66
18	The molecular basis of galactosemia â€” Past, present and future. Gene, 2016, 589, 133-141.	2.2	66

#	Article	IF	Citations
19	LGR5 receptor promotes cellâ€“cell adhesion in stem cells and colon cancer cells via the IQGAP1â€“Rac1 pathway. Journal of Biological Chemistry, 2017, 292, 14989-15001.	3.4	57
20	Fine tuning the myosin motor: the role of the essential light chain in striated muscle myosin. Biochimie, 2003, 85, 639-645.	2.6	56
21	FAD binding overcomes defects in activity and stability displayed by cancer-associated variants of human NQO1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2163-2173.	3.8	56
22	NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places. Bioscience Reports, 2019, 39, .	2.4	55
23	Molecular Structure of Saccharomyces cerevisiae Gal1p, a Bifunctional Galactokinase and Transcriptional Inducer. Journal of Biological Chemistry, 2005, 280, 36905-36911.	3.4	54
24	Substrate Specificity and Mechanism from the Structure of Pyrococcus furiosus Galactokinase. Journal of Molecular Biology, 2004, 337, 387-398.	4.2	53
25	Kinetic analysis of yeast galactokinase: implications for transcriptional activation of the GAL genes. Biochimie, 2002, 84, 265-272.	2.6	52
26	The structural and molecular biology of type III galactosemia. IUBMB Life, 2006, 58, 83-89.	3.4	52
27	Glycerol enhances fungal germination at the waterâ€activity limit for life. Environmental Microbiology, 2017, 19, 947-967.	3.8	52
28	Fasciola hepatica expresses multiple Î±- and Î²-tubulin isotypes. Molecular and Biochemical Parasitology, 2008, 159, 73-78.	1.1	48
29	LIAD-fs scheme for studies of ultrafast laser interactions with gas phase biomolecules. Physical Chemistry Chemical Physics, 2012, 14, 6289.	2.8	45
30	Misfolding of galactose 1-phosphate uridylyltransferase can result in type I galactosemia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1279-1293.	3.8	44
31	Identification and characterisation of human aldose 1-epimerase. FEBS Letters, 2003, 543, 21-24.	2.8	43
32	Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase. FEBS Journal, 2005, 272, 6170-6177.	4.7	43
33	Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii. Journal of the Science of Food and Agriculture, 2017, 97, 3039-3049.	3.5	43
34	Size and Charge Requirements for Kinetic Modulation and Actin Binding by Alkali 1-type Myosin Essential Light Chains. Journal of Biological Chemistry, 1999, 274, 18271-18277.	3.4	42
35	Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism. Current Drug Targets, 2017, 18, 500-510.	2.1	41
36	Gal3p and Gal1p interact with the transcriptional repressor Gal80p to form a complex of 1:1 stoichiometry. Biochemical Journal, 2002, 363, 515.	3.7	40

#	Article	IF	Citations
37	Sugar recognition by human galactokinase. BMC Biochemistry, 2003, 4, 16.	4.4	40
38	Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands. Scientific Reports, 2016, 6, 20331.	3.3	39
39	Effects of Alcohols and Compatible Solutes on the Activity of Î²-Galactosidase. Applied Biochemistry and Biotechnology, 2013, 169, 786-794.	2.9	38
40	Gal3p and Gal1p interact with the transcriptional repressor Gal80p to form a complex of 1:1 stoichiometry. Biochemical Journal, 2002, 363, 515-520.	3.7	36
41	Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism. Scientific Reports, 2017, 7, 44532.	3.3	35
42	Molecular Structure of Human Galactose Mutarotase. Journal of Biological Chemistry, 2004, 279, 23431-23437.	3.4	34
43	Structural and molecular biology of type I galactosemia: Diseaseâ€associated mutations. IUBMB Life, 2011, 63, 949-954.	3.4	34
44	Enhanced vulnerability of human proteins towards disease-associated inactivation through divergent evolution. Human Molecular Genetics, 2017, 26, 3531-3544.	2.9	34
45	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6246-6254.	2.2	33
46	Glycosaminoglycans in human retinoblastoma cells: heparan sulfate, a modulator of the pigment epithelium-derived factor-receptor interactions. BMC Biochemistry, 2003, 4, 1.	4.4	32
47	Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms. Current Drug Targets, 2016, 17, 1506-1514.	2.1	31
48	The Mechanism of Action of Praziquantel: Six Hypotheses. Current Topics in Medicinal Chemistry, 2018, 18, 1575-1584.	2.1	31
49	Damage to plasmid DNA induced by low energy carbon ions. Physics in Medicine and Biology, 2007, 52, 3729-3740.	3.0	30
50	IQ-motif selectivity in human IQGAP2 and IQGAP3: binding of calmodulin and myosin essential light chain. Bioscience Reports, 2011, 31, 371-379.	2.4	30
51	Altered cofactor binding affects stability and activity of human UDP-galactose 4â€²-epimerase: Implications for type III galactosemia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1516-1526.	3.8	30
52	GHMP Kinases - Structures, Mechanisms and Potential for Therapeutically Relevant Inhibition. Current Enzyme Inhibition, 2007, 3, 77-94.	0.4	29
53	Analysis of UDPâ€galactose 4â€²â€epimerase mutations associated with the intermediate form of type III galactosaemia. Journal of Inherited Metabolic Disease, 2008, 31, 108-116.	3.6	27
54	Development and implementation of split-GFP-based bimolecular fluorescence complementation (BiFC) assays in yeast. Biochemical Society Transactions, 2008, 36, 479-482.	3.4	27

#	Article	IF	Citations
55	Biochemical characterisation of triose phosphate isomerase fromÂtheÂliver fluke Fasciola hepatica. Biochimie, 2013, 95, 2182-2189.	2.6	27
56	The two common polymorphic forms of human NRHâ€quinone oxidoreductase 2 (NQO2) have different biochemical properties. FEBS Letters, 2014, 588, 1666-1672.	2.8	26
57	IQGAP1 Interaction with RHO Family Proteins Revisited. Journal of Biological Chemistry, 2016, 291, 26364-26376.	3.4	26
58	The Mechanism of Action of Praziquantel: Can New Drugs Exploit Similar Mechanisms?. Current Medicinal Chemistry, 2020, 27, 676-696.	2.4	26
59	IQ-motif peptides as novel anti-microbial agents. Biochimie, 2013, 95, 875-880.	2.6	25
60	The metastability of human UDP-galactose 4â€²-epimerase (GALE) is increased by variants associated with type III galactosemia but decreased by substrate and cofactor binding. Archives of Biochemistry and Biophysics, 2014, 562, 103-114.	3.0	25
61	Fructose 1,6-bisphosphatase: getting the message across. Bioscience Reports, 2019, 39, .	2.4	25
62	Yeast Cellular Stress: Impacts on Bioethanol Production. Fermentation, 2020, 6, 109.	3.0	24
63	In silico prediction of the effects of mutations in the human UDP-galactose 4â€²-epimerase gene: Towards a predictive framework for type III galactosemia. Gene, 2013, 524, 95-104.	2.2	23
64	The rÃ1e of the proline-rich region in A1-type myosin essential light chains: implications for information transmission in the actomyosin complex. FEBS Letters, 1997, 400, 31-36.	2.8	22
65	Triose phosphate isomerase from the blood fluke Schistosoma mansoni: Biochemical characterisation of a potential drug and vaccine target. FEBS Letters, 2013, 587, 3422-3427.	2.8	22
66	FhCaBP3: A Fasciola hepatica calcium binding protein with EF-hand and dynein light chain domains. Biochimie, 2013, 95, 751-758.	2.6	22
67	Role of Arg228 in the Phosphorylation of Galactokinase: The Mechanism of GHMP Kinases by Quantum Mechanics/Molecular Mechanics Studies. Biochemistry, 2013, 52, 4858-4868.	2.5	22
68	Comparative biochemical analysis of three members of the Schistosoma mansoni TAL family: Differences in ion and drug binding properties. Biochimie, 2015, 108, 40-47.	2.6	22
69	The Catalytic Cycle of the Antioxidant and Cancer-Associated Human NQO1 Enzyme: Hydride Transfer, Conformational Dynamics and Functional Cooperativity. Antioxidants, 2020, 9, 772.	5.1	22
70	IQ motif selectivity in human IQGAP1: binding of myosin essential light chain and S100B. Molecular and Cellular Biochemistry, 2008, 318, 43-51.	3.1	21
71	Functional domains of the human epididymal protease inhibitor, eppin. FEBS Journal, 2008, 275, 1742-1750.	4.7	21
72	Antiproton induced DNA damage: proton like in flight, carbon-ion like near rest. Scientific Reports, 2013, 3, 1770.	3.3	21

#	Article	IF	Citations
73	In Silico Prediction of the Effects of Mutations in the Human Mevalonate Kinase Gene: Towards a Predictive Framework for Mevalonate Kinase Deficiency. Annals of Human Genetics, 2015, 79, 451-459.	0.8	21
74	Calmodulin disruption impacts growth and motility in juvenile liver fluke. Parasites and Vectors, 2016, 9, 46.	2.5	21
75	A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer. Biomolecules, 2019, 9, 728.	4.0	21
76	The role of the active site residues in human galactokinase: Implications for the mechanisms of GHMP kinases. Bioorganic Chemistry, 2011, 39, 120-126.	4.1	20
77	Liver fluke Î²-tubulin isotype 2 binds albendazole and is thus a probable target of this drug. Parasitology Research, 2010, 107, 1257-1264.	1.6	19
78	Artemisinins act through at least two targets in a yeast model. FEMS Yeast Research, 2011, 11, 233-237.	2.3	19
79	FhCaBP4: a Fasciola hepatica calcium-binding protein with EF-hand and dynein light chain domains. Parasitology Research, 2012, 111, 1707-1713.	1.6	19
80	Characterization of theSaccharomyces cerevisiaegalactose mutarotase/UDP-galactose 4-epimerase protein, Gal10p. FEMS Yeast Research, 2007, 7, 366-371.	2.3	18
81	Detection and localisation of proteinâ€“protein interactions in Saccharomyces cerevisiae using a split-GFP method. Fungal Genetics and Biology, 2008, 45, 597-604.	2.1	18
82	In vivo and inÂvitro function of human UDP-galactose 4â€²-epimerase variants. Biochimie, 2011, 93, 1747-1754.	2.6	18
83	The interaction of IQGAPs with calmodulin-like proteins. Biochemical Society Transactions, 2011, 39, 694-699.	3.4	17
84	Comparison of dynamics of wildtype and V94M human UDP-galactose 4-epimeraseâ€”A computational perspective on severe epimerase-deficiency galactosemia. Gene, 2013, 526, 318-324.	2.2	17
85	Four Challenges for Better Biocatalysts. Fermentation, 2019, 5, 39.	3.0	17
86	New model for the interaction of IQGAP1 with CDC42 and RAC1. Small GTPases, 2020, 11, 16-22.	1.6	17
87	Metabolic Enzymes of Helminth Parasites: Potential as Drug Targets. Current Protein and Peptide Science, 2016, 17, 280-295.	1.4	17
88	Characterisation of two calmodulin-like proteins from the liver fluke, Fasciola hepatica. Biological Chemistry, 2007, 388, 593-599.	2.5	16
89	DNA damage by low-energy ions. Biochemical Society Transactions, 2009, 37, 893-896.	3.4	16
90	Increased Promiscuity of Human Galactokinase Following Alteration of a Single Amino Acid Residue Distant from the Active Site. ChemBioChem, 2011, 12, 2081-2087.	2.6	16

#	Article	IF	Citations
91	A mysterious family of calcium-binding proteins from parasitic worms. Biochemical Society Transactions, 2016, 44, 1005-1010.	3.4	16
92	Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1). ChemBioChem, 2019, 20, 2841-2849.	2.6	16
93	Biochemical analysis of the interactions of IQGAP1 C-terminal domain with CDC42. World Journal of Biological Chemistry, 2012, 3, 53.	4.3	16
94	Binding of serum albumin to the anthelmintic drugs albendazole, triclabendazole and their sulphoxides. Veterinary Parasitology, 2010, 171, 172-175.	1.8	15
95	The structural and molecular biology of type I galactosemia: Enzymology of galactose 1-phosphate uridylyltransferase. IUBMB Life, 2011, 63, n/a-n/a.	3.4	15
96	Differential expression of liver fluke Î²-tubulin isotypes at selected life cycle stages. International Journal for Parasitology, 2013, 43, 1133-1139.	3.1	15
97	Biochemical characterisation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the liver fluke, Fasciola hepatica. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 744-749.	2.3	15
98	Interactions of the 67 kDa laminin receptor and its precursor with laminin. Bioscience Reports, 2010, 30, 73-79.	2.4	14
99	The Molecular Dynamics of Trypanosoma brucei UDPâ€Galactose 4â€²â€Epimerase: A Drug Target for African Sleeping Sickness. Chemical Biology and Drug Design, 2012, 80, 173-181.	3.2	14
100	Purple sweet potato colour â€“ a potential therapy for galactosemia?. International Journal of Food Sciences and Nutrition, 2014, 65, 391-393.	2.8	14
101	Galactokinase promiscuity: a question of flexibility?. Biochemical Society Transactions, 2016, 44, 116-122.	3.4	14
102	The roles and applications of chaotropes and kosmotropes in industrial fermentation processes. World Journal of Microbiology and Biotechnology, 2020, 36, 89.	3.6	14
103	Galactokinase deficiency: lessons from the GalNet registry. Genetics in Medicine, 2021, 23, 202-210.	2.4	14
104	Mechanistic studies on humanN-acetylgalactosamine kinase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 370-376.	5.2	13
105	A novel calmodulin-like protein from the liver fluke, Fasciola hepatica. Biochimie, 2012, 94, 2398-2406.	2.6	13
106	Different specificities of two aldehyde dehydrogenases from Saccharomyces cerevisiae var. boulardii. Bioscience Reports, 2017, 37, .	2.4	12
107	Type IV galactosemia. Genetics in Medicine, 2019, 21, 1283-1285.	2.4	12
108	Novel and selective inactivators of Triosephosphate isomerase with anti-trematode activity. Scientific Reports, 2020, 10, 2587.	3.3	12

#	Article	IF	Citations
109	Galactosemia: Towards Pharmacological Chaperones. Journal of Personalized Medicine, 2021, 11, 106.	2.5	12
110	Targeting HIF-1Î± Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1. Journal of Personalized Medicine, 2022, 12, 747.	2.5	12
111	A calcium-dependent interaction between calmodulin and the calponin homology domain of human IQGAP1. Molecular and Cellular Biochemistry, 2012, 371, 217-223.	3.1	11
112	Modulating Mobility: a Paradigm for Protein Engineering?. Applied Biochemistry and Biotechnology, 2017, 181, 83-90.	2.9	11
113	The tegumental allergen-like proteins of Schistosoma mansoni: A biochemical study of SmTAL4-TAL13. Molecular and Biochemical Parasitology, 2018, 221, 14-22.	1.1	11
114	FhCaBP2: a Fasciola hepatica calcium-binding protein with EF-hand and dynein light chain domains. Parasitology, 2015, 142, 1375-1386.	1.5	10
115	Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer. Handbook of Experimental Pharmacology, 2017, 245, 155-190.	1.8	10
116	Insight into the mechanism of galactokinase: Role of a critical glutamate residue and helix/coil transitions. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 321-328.	2.3	10
117	The structural and molecular biology of type IV galactosemia. Biochimie, 2021, 183, 13-17.	2.6	10
118	A plasma membrane Ca2+-ATPase (PMCA) from the liver fluke, Fasciola hepatica. International Journal for Parasitology, 2012, 42, 851-858.	3.1	9
119	Fragmentation of Neutral Amino Acids and Small Peptides by Intense, Femtosecond Laser Pulses. Journal of the American Society for Mass Spectrometry, 2013, 24, 1366-1375.	2.8	9
120	TheSaccharomyces cerevisiaequinone oxidoreductase Lot6p: stability, inhibition and cooperativity. FEMS Yeast Research, 2014, 14, 797-807.	2.3	9
121	Quantitative Enzymology. Current Enzyme Inhibition, 2015, 11, 12-31.	0.4	9
122	Reaction Mechanism of Isopentenyl Phosphate Kinase: A QM/MM Study. Journal of Physical Chemistry B, 2017, 121, 11062-11071.	2.6	9
123	On the Interaction Between Human IQGAP1 and Actin. Protein and Peptide Letters, 2016, 23, 386-395.	0.9	9
124	Nucleotide sequence, heterologous expression and novel purification of DNA ligase from Bacillus stearothermophilus. BBA - Proteins and Proteomics, 1999, 1432, 413-418.	2.1	8
125	Phosphorylation Mechanism of Phosphomevalonate Kinase: Implications for Rational Engineering of Isoprenoid Biosynthetic Pathway Enzymes. Journal of Physical Chemistry B, 2016, 120, 10714-10722.	2.6	8
126	Experimental and computational evidence on conformational fluctuations as a source of catalytic defects in genetic diseases. RSC Advances, 2016, 6, 58604-58612.	3.6	8

#	Article	IF	Citations
127	Improving the Activity and Stability of Human Galactokinase for Therapeutic and Biotechnological Applications. ChemBioChem, 2018, 19, 1088-1095.	2.6	8
128	Evidence for chaotropicity/kosmotropicity offset in a yeast growth model. Biotechnology Letters, 2019, 41, 1309-1318.	2.2	8
129	Catalytic mechanism of mevalonate kinase revisited, a QM/MM study. Organic and Biomolecular Chemistry, 2019, 17, 2423-2431.	2.8	8
130	Therapies for galactosemia: a patent landscape. Pharmaceutical Patent Analyst, 2020, 9, 45-51.	1.1	8
131	Detection of Protein-Protein Interactions Using Protein-Fragment Complementation Assays (PCA). Current Proteomics, 2007, 4, 17-27.	0.3	7
132	Development of a novel mass spectrometric technique for studying DNA damage. Biochemical Society Transactions, 2009, 37, 905-909.	3.4	7
133	Fasciola hepatica calcium-binding protein FhCaBP2: structure of the dynein light chain-like domain. Parasitology Research, 2016, 115, 2879-2886.	1.6	7
134	FhCaBP1 (FH22): A Fasciola hepatica calcium-binding protein with EF-hand and dynein light chain domains. Experimental Parasitology, 2016, 170, 109-115.	1.2	7
135	In silico prediction of the effects of mutations in the human triose phosphate isomerase gene: Towards a predictive framework for TPI deficiency. European Journal of Medical Genetics, 2017, 60, 289-298.	1.3	7
136	Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity. Bioscience Reports, 2019, 39, .	2.4	7
137	Interactions between the budding yeast IQGAP homologue Iqg1p and its targets revealed by a split-EGFP bimolecular fluorescence complementation assay. Cell Biology International, 2008, 32, 1318-1322.	3.0	6
138	Split-EGFP Screens for the Detection and Localisation of Proteinâ€“Protein Interactions in Living Yeast Cells. Methods in Molecular Biology, 2010, 638, 303-317.	0.9	6
139	Citrate synthase from the liver fluke Fasciola hepatica. Parasitology Research, 2013, 112, 2413-2417.	1.6	6
140	UDP-galactose 4â€²-epimerase from the liver fluke, Fasciola hepatica: biochemical characterization of the enzyme and identification of inhibitors. Parasitology, 2015, 142, 463-472.	1.5	6
141	Calmodulins from Schistosoma mansoni: Biochemical analysis and interaction with IQ-motifs from voltage-gated calcium channels. Cell Calcium, 2018, 74, 1-13.	2.4	6
142	Galactokinases: Potential Biotechnological Applications as Biocatalysts. Current Biotechnology, 2012, 1, 148-154.	0.4	6
143	Characterisation of eppin function: expression and activity in the lung. European Respiratory Journal, 2017, 50, 1601937.	6.7	5
144	Value of predictive bioinformatics in inherited metabolic diseases. World Journal of Medical Genetics, 2015, 5, 46.	1.0	5

#	Article	IF	Citations
145	L-Asparaginase from Penicillium sizovae Produced by a Recombinant Komagataella phaffii Strain. Pharmaceuticals, 2022, 15, 746.	3.8	5
146	Conformational changes to plasmid DNA induced by low energy carbon ions. Journal of Physics: Conference Series, 2007, 58, 355-358.	0.4	4
147	The contribution of key hydrophobic residues in ecotin to enzyme-inhibitor complex stability. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1207-1210.	5.2	4
148	Experimental setup and first measurement of DNA damage induced along and around an antiproton beam. European Physical Journal D, 2010, 60, 209-214.	1.3	4
149	Interaction of prothrombin with a phospholipid surface: evidence for a membrane-induced conformational change. Molecular and Cellular Biochemistry, 2011, 348, 109-115.	3.1	4
150	Characterization of Cd36_03230p, a putative vanillin dehydrogenase from Candida dubliniensis. RSC Advances, 2016, 6, 99774-99780.	3.6	4
151	RNA interference dynamics in juvenile Fasciola hepatica are altered during in vitro growth and development. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 14, 46-55.	3.4	4
152	The Schistosoma mansoni tegumental allergen protein, SmTAL1: Binding to an IQ-motif from a voltage-gated ion channel and effects of praziquantel. Cell Calcium, 2020, 86, 102161.	2.4	4
153	Praziquantel: An Enigmatic, Yet Effective, Drug. Methods in Molecular Biology, 2020, 2151, 1-8.	0.9	4
154	Formation of gas phase macromolecular targets by laser desorption from surfaces. Journal of Physics: Conference Series, 2008, 101, 012016.	0.4	3
155	Effects of low energy carbon ions on plasmid DNA. Journal of Physics: Conference Series, 2008, 101, 012012.	0.4	3
156	IR laser desorption of oligonucleotides. European Physical Journal D, 2010, 60, 163-169.	1.3	3
157	N-acetylgalactosamine Kinase: A Naturally Promiscuous Small Molecule Kinase. Applied Biochemistry and Biotechnology, 2012, 166, 57-63.	2.9	3
158	Water-mediated network in the resistance mechanism of fosfomycin. Physical Chemistry Chemical Physics, 2018, 20, 21660-21667.	2.8	3
159	Repurposing drugs for the treatment of galactosemia. Expert Opinion on Orphan Drugs, 2019, 7, 443-451.	0.8	3
160	Phosphorylation Mechanism of N-Acetyl-<scp>l</scp>-glutamate Kinase, a QM/MM Study. Journal of Physical Chemistry B, 2019, 123, 2844-2852.	2.6	3
161	Myosin Va and spermine synthase: partners in exosome transport. Bioscience Reports, 2019, 39, .	2.4	3
162	In silico analysis of the effects of disease-associated mutations of Î²-hexosaminidase A in Tayâ€'Sachs disease. Journal of Genetics, 2020, 99, 1.	0.7	3

#	Article	IF	Citations
163	The GAL genetic switch: visualisation of the interacting proteins by splitâ€EGFP bimolecular fluorescence complementation. Journal of Basic Microbiology, 2011, 51, 312-317.	3.3	2
164	Plume characteristics and dynamics of UV and IR laser-desorbed oligonucleotides. International Journal of Biological Macromolecules, 2012, 50, 1081-1090.	7.5	2
165	Disturbed cofactor binding by a novel mutation in UDP-galactose 4â€²-epimerase results in a type III galactosemia phenotype at birth. RSC Advances, 2016, 6, 17297-17301.	3.6	2
166	Modulation of the mobility of a key region in human galactokinase: Impacts on catalysis and stability. Bioorganic Chemistry, 2018, 81, 649-657.	4.1	2
167	Dynamic origins of substrate promiscuity in bacterial galactokinases. Carbohydrate Research, 2019, 486, 107839.	2.3	2
168	Galactosemia: opportunities for novel therapies. , 2020, , 221-245.		2
169	UDP-Galactose-4-Epimerase (GALE). , 2014, , 1449-1464.		2
170	Plume Image Profiling of UV Laser Desorbed Biomolecules. , 2008, , .		1
171	Pilot Evaluation of Two Fasciola hepatica Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics. Molecules, 2020, 25, 3477.	3.8	1
172	Destressing Yeast for Higher Biofuel Yields: Can Excess Chaotropicity Be Mitigated?. Applied Biochemistry and Biotechnology, 2020, 192, 1368-1375.	2.9	1
173	In SilicoAnalysis of the Effects of Point Mutations on Î±-Globin: Implications for Î±-Thalassemia. Hemoglobin, 2020, 44, 89-103.	0.8	1
174	Serine Proteases in Bone Disease. Current Rheumatology Reviews, 2009, 5, 141-147.	0.8	1
175	A ligand predication tool based on modeling and reasoning with imprecise probabilistic knowledge. Computer Methods and Programs in Biomedicine, 2010, 98, 45-54.	4.7	0
176	A galactokinase-like protein from the liver fluke Fasciola hepatica. Experimental Parasitology, 2018, 192, 65-72.	1.2	0
177	Characterization of Calcium-Binding Proteins from Parasitic Worms. Methods in Molecular Biology, 2019, 1929, 615-641.	0.9	0
178	Escherichia coli Modulator of Drug Activity B (MdaB) Has Different Enzymological Properties to Eukaryote Quinone Oxidoreductases. Helvetica Chimica Acta, 2019, 102, e1900135.	1.6	0
179	[13 C]â€galactose breath test in a patient with galactokinase deficiency and spastic diparesis. JIMD Reports, 2021, 59, 104-109.	1.5	0
180	Cause or Effect: Which Genetic Changes Are Associated With Cancer?. Gene, Cell and Tissue, 2014, 1, .	0.2	0

#	Article	IF	Citations
181	analysis of the effects of disease-associated mutations of Î²-hexosaminidase A in Tay-Sachs disease. Journal of Genetics, 2020, 99, .	0.7	0
182	Expression, purification and crystallization of a novel metagenome-derived salicylaldehyde dehydrogenase from Alpine soil. Acta Crystallographica Section F, Structural Biology Communications, 2022, 78, 161-169.	0.8	0